Fusion Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Fusion Pharmaceuticals has a total shareholder equity of $241.8M and total debt of $49.7M, which brings its debt-to-equity ratio to 20.5%. Its total assets and total liabilities are $323.8M and $82.0M respectively.
Key information
20.5%
Debt to equity ratio
US$49.69m
Debt
| Interest coverage ratio | n/a |
| Cash | US$210.53m |
| Equity | US$241.83m |
| Total liabilities | US$81.98m |
| Total assets | US$323.81m |
Recent financial health updates
Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?
Jan 30
Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?
Aug 10We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Jan 16We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Aug 28We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely
Apr 05Recent updates
Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook
Mar 03Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?
Jan 30Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors
Sep 16Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment
Aug 29Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?
Aug 10Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M
Aug 09Fusion Pharma wins FDA nod to start trials for solid tumor candidate
Jun 23We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Jan 16We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Aug 28Fusion Pharma trades higher on early-stage data for cancer therapy
Jun 14We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely
Apr 05How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?
Mar 01Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?
Jan 25Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation
Dec 21Fusion Pharmaceuticals EPS misses by $0.04
Nov 10Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer
Nov 02Financial Position Analysis
Short Term Liabilities: FUSN's short term assets ($220.9M) exceed its short term liabilities ($20.8M).
Long Term Liabilities: FUSN's short term assets ($220.9M) exceed its long term liabilities ($61.2M).
Debt to Equity History and Analysis
Debt Level: FUSN has more cash than its total debt.
Reducing Debt: FUSN's debt to equity ratio has increased from 3.8% to 20.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FUSN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FUSN has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 31.4% each year.